Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes (SEMA-CKM)
Real-world Canadian Retrospective Study Evaluating Longitudinal SEMAglutide Use on Cardio-Kidney-Metabolic Outcomes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Lisa Chu, PhD
- Phone Number: (416) 645-2929
- Email: lisa.chu@lmc.ca
Study Contact Backup
- Name: giovana Romero, Msc
- Phone Number: (416) 645-2929
- Email: giovana.romero@lmc.ca
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
T2D Cohort:
- A clinical diagnosis of T2D ≥ 1 year
- HbA1c ≥ 6.5% (pre-index date)
- Initiated semaglutide or other AHA(s) before January 1st, 2023*
- Seen by an LMC endocrinologist in the last 18 months as of the query date
- ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date
- Informed data consent for their medical record data to be used for research purposes
Obesity Cohort:
- 18 years or older
- BMI ≥ 27 kg/m2
- HbA1c < 6.5% (pre-index date)
- Initiated semaglutide before January 1st, 2023*
- Seen by an LMC endocrinologist in the last 18 months as of the query date
- ≥ one HbA1c value up to 6 months (± 90 days) prior to index date
- Informed data consent for their medical record data to be used for research purposes
Exclusion Criteria:
- Clinical diagnosis of type 1 diabetes/latent autoimmune diabetes in adults (LADA)
- Clinical diagnosis of T2D (obesity cohort only)
- Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period
- Documented history or family history of medullary thyroid carcinoma
- Participation in a research study with an Investigational Product
- eGFR < 15 mL/min/1.73m2 at index date
- Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort)
- Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
T2D Semaglutide Cohort
Adults with T2D prescribed semaglutide
|
participants who initiate semaglutide
|
|
T2D other AHA cohort
Adults with T2D prescribed antihyperglycemic medication beside semaglutide including sulfonylurea, DPP4i, and/or SGLT2i
|
|
|
Obesity Semaglutide Cohort
Adults with obesity, defined as BMI equal or greater than 27 kg/m2, prescribed semaglutide
|
participants who initiate semaglutide
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HbA1c- 3 Years
Time Frame: Baseline to 3 Years
|
The primary outcome measure is investigating the change in HbA1c from baseline to 3 years (± 90 days) among adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs
|
Baseline to 3 Years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HbA1c- 1 Year
Time Frame: Baseline to 1 year
|
Comparing the change in HbA1c between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 year
|
|
Change in HbA1c- 2 Years
Time Frame: Baseline to 2 Years
|
Comparing the change in HbA1c between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Proportion of individuals who achieve HbA1c ≤ 7.0% - 1 Year
Time Frame: Baseline to 1 Year
|
comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Proportion of individuals who achieve HbA1c ≤ 7.0%- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Proportion of individuals who achieve HbA1c ≤ 7.0% - 3 Years
Time Frame: Baseline to 3 Years
|
comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in body weight- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in body weight- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in body weight- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Percent body weight loss ≥ 5% - 1 Year
Time Frame: Baseline to 1 Year
|
comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Percent body weight loss ≥ 5% - 2 Years
Time Frame: Baseline to 2 Years
|
comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Percent body weight loss ≥ 5% - 3 Years
Time Frame: Baseline to 3 Years
|
comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Percent body weight loss ≥ 10% - 1 Year
Time Frame: Baseline to 1 Year
|
comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Percent body weight loss ≥ 10% - 2 Years
Time Frame: Baseline to 2 Years
|
comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Percent body weight loss ≥ 10% - 3 Years
Time Frame: Baseline to 3 Years
|
comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Percent body weight loss ≥ 15% - 1 Year
Time Frame: Baseline to 1 Year
|
comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Percent body weight loss ≥ 15%- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Percent body weight loss ≥ 15%- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in BMI- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the change in BMI (kg/m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in BMI- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the change in BMI (kg/m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in BMI- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in BMI (kg/m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in Waist Circumference- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in Waist Circumference- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in Waist Circumference- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in Blood Pressure- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in Blood Pressure- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in Blood Pressure- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in eGFR- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the change in eGFR (ml/min1.73m^2)
between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in eGFR- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the change in eGFR (ml/min1.73m^2)
between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in eGFR- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in eGFR (ml/min1.73m^2)
between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Proportion of individuals with ≥ 50% decline in eGFR- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Proportion of individuals with ≥ 50% decline in eGFR- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Proportion of individuals with ≥ 50% decline in eGFR- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in uACR- 1 year
Time Frame: Baseline to 1 Year
|
comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in uACR- 2 years
Time Frame: Baseline to 2 Years
|
comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in uACR- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in ALT- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in ALT- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in ALT- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in Lipids- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in Lipids- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in Lipids- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Number of non-semaglutide GLP-1-based therapies- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Number of non-semaglutide GLP-1-based therapies- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Number of non-semaglutide GLP-1-based therapies- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in insulin use- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in Insulin- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in Insulin- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Change in TDD of insulin- 1 Year
Time Frame: Baseline to 1 Year
|
comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 1 Year
|
|
Change in TDD of insulin- 2 Years
Time Frame: Baseline to 2 Years
|
comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 2 Years
|
|
Change in TDD of insulin- 3 Years
Time Frame: Baseline to 3 Years
|
comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
|
Baseline to 3 Years
|
|
Incidence of non-acetylsalicylic acid antiplatelet use
Time Frame: Baseline to Endpoint
|
comparing the incidence of non-acetylsalicylic acid antiplatelet use between adults with T2D treated with 1 or more years of semaglutide and adults with T2D treated with 1 or more years of other AHAs in the cardiovascular sub-cohort
|
Baseline to Endpoint
|
|
Percent body weight loss ≥ 5%
Time Frame: Baseline to 1 Year
|
Comparing the percent body weight loss ≥ 5% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
Percent body weight loss ≥ 10%
Time Frame: Baseline to 1 Year
|
Comparing the percent body weight loss ≥ 10% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
Percent body weight loss ≥ 15%
Time Frame: Baseline to 1 Year
|
Comparing the percent body weight loss ≥ 15% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
Body Weight
Time Frame: Baseline to 1 Year
|
Comparing body weight (kg) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
BMI
Time Frame: Baseline to 1 Year
|
Comparing BMI (km/m^2) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
Waist Circumference
Time Frame: Baseline to 1 Year
|
Comparing the waist circumference (cm) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
HbA1c
Time Frame: Baseline to 1 Year
|
Comparing HbA1c (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
Percent of new onset pre-diabetes
Time Frame: Baseline to 1 Year
|
Comparing the percent of new onset pre-diabetes (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
Percent of new onset T2D
Time Frame: Baseline to 1 Year
|
Comparing the percent of new onset T2D (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
Blood Pressure
Time Frame: Baseline to 1 Year
|
Comparing blood pressure in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
eGFR
Time Frame: Baseline to 1 year
|
Comparing eGFR (ml/min1.73m^2) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 year
|
|
uACR
Time Frame: Baseline to 1 Year
|
Comparing uACR (mg/mmol) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
ALT
Time Frame: Baseline to 1 Year
|
Comparing ALT (U/L) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
|
Lipids
Time Frame: Baseline to 1 Year
|
Comparing lipids (triglycerides, LDL-C, HDL-C , total cholesterol) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
|
Baseline to 1 Year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1c
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing HbA1c between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
|
Proportion of individuals who achieve HbA1c ≤ 7.0%
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
|
Body Weight
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing body weight (kg) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
|
Percent body weight loss ≥ 5%
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing percent body weight loss ≥ 5% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
|
Percent body weight loss ≥ 10%
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing percent body weight loss ≥ 10% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
|
Percent body weight loss ≥ 15%
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing percent body weight loss ≥ 15% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
|
BMI
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing BMI (kg/m^2) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
|
eGFR
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing eGFR (ml/min1.73m^2)
between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
|
Proportion of individuals with ≥ 50% decline in eGFR
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing the proportion of individuals with ≥ 50% decline in eGFR between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
|
uACR
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing uACR (mg/mmol) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
|
ALT
Time Frame: Baseline to Endpoint (3 Years)
|
Comparing ALT (U/L) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
|
Baseline to Endpoint (3 Years)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SEMA-CKM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.